These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37265418)

  • 1. Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers.
    Bathgate CJ; Muther E; Georgiopoulos AM; Smith B; Tillman L; Graziano S; Verkleij M; Lomas P; Quittner A
    Pediatr Pulmonol; 2023 Sep; 58(9):2469-2477. PubMed ID: 37265418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis.
    Zhang L; Albon D; Jones M; Bruschwein H
    Ther Adv Respir Dis; 2022; 16():17534666221144211. PubMed ID: 36562554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults.
    Graziano S; Boldrini F; Pellicano GR; Milo F; Majo F; Cristiani L; Montemitro E; Alghisi F; Bella S; Cutrera R; Fiocchi AG; Quittner A; Tabarini P
    Chest; 2024 Apr; 165(4):800-809. PubMed ID: 37925143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suicide attempts in adolescents with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Arslan M; Chalmers S; Rentfrow K; Olson JM; Dean V; Wylam ME; Demirel N
    J Cyst Fibros; 2023 May; 22(3):427-430. PubMed ID: 36759252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey assessing the impact of COVID-19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis.
    Sakon C; Vogt H; Brown CD; Tillman EM
    Pediatr Pulmonol; 2023 Mar; 58(3):662-664. PubMed ID: 36482831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
    Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
    Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals.
    Almulhem M; Harnett N; Graham S; Haq I; Visram S; Ward C; Brodlie M
    BMJ Open Respir Res; 2022 Oct; 9(1):. PubMed ID: 36207030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM
    J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.
    Jordan KD; Zemanick ET; Taylor-Cousar JL; Hoppe JE
    Expert Rev Respir Med; 2023 Feb; 17(2):97-108. PubMed ID: 36803356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.
    Milo F; Ciciriello F; Alghisi F; Tabarini P
    J Cyst Fibros; 2023 May; 22(3):414-419. PubMed ID: 36549989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor.
    Baroud E; Chaudhary N; Georgiopoulos AM
    Pediatr Pulmonol; 2023 Jul; 58(7):1920-1930. PubMed ID: 37036050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.
    Ørum MB; Rönsholt FF; Jeppesen M; Bendstrup E; Katzenstein TL; Ott P; Perch M; Pressler T; Qvist T; Jensen-Fangel S
    Pediatr Pulmonol; 2023 Feb; 58(2):602-605. PubMed ID: 36314653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.
    Caley LR; Jarosz-Griffiths HH; Smith L; Gale L; Barrett J; Kinsey L; Davey V; Nash M; Jones AM; Whitehouse JL; Shimmin D; Floto RA; White H; Peckham DG
    J Cyst Fibros; 2023 Nov; 22(6):1002-1009. PubMed ID: 37422432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding.
    Jain R; Wolf A; Molad M; Taylor-Cousar J; Esther CR; Shteinberg M
    J Cyst Fibros; 2022 Nov; 21(6):1074-1076. PubMed ID: 36266182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.